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Introduction 
With the advancement of technology and availability of mechanical 
circulatory support (MCS) devices for the treatment of acute decompensated 
systolic HF in the 21st century, the role of inotropes is becoming obsolete. 
Medical therapy for acute decompensated heart failure (HF) has not changed 
since 1960’s, we still use supplemental oxygen, diuretics, vasodilators and 
inotropes to improve congestion, cardiac output, end organ perfusion and 
symptoms related to elevate filling pressures1.  Despite demonstrated 
improvements in hemodynamics, the uses of inotropes have not demonstrated 
any improvements in mortality. Mechanical circulatory support (MCS) use is 
growing rapidly in the USA, in patients with stage D HF both as destination 
therapy and as a bridge to cardiac transplantation.  In both, transplant-eligible 
and non-transplant-eligible patients, improvement in end-organ perfusion, 
functional capacity, quality of life and most importantly mortality have been 
demonstrated.  In this perspective paper we are going to discuss the current lack 
of evidence for inotropic therapy and the evolving benefit of MCS in end-stage 
systolic HF patients.  
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Inotropes in End-Stage HF  
Advanced HF with cardiogenic shock, are syndromes characterized in many 
patients by a reduction in myocardial contractile force. Medical therapy is still 
considered the mainstay for acute decompensated HF. The guidelines 
recommend diuretic therapy, which decreases intracardiac filling pressures and 
relieve congestion 2-4 This has to be accompanied with medications favoring left 
ventricular reverse remodeling such as angiotensin-converting enzyme inhibitors 
(ACEI) 5, angiotensin receptors blockers6, beta blockers7, aldosterone blockers8, 
and nitrate/hydralazine 9. As the disease progresses, compensatory mechanisms 
fail, and cardiac output decreases (stage D HF).  
 Inotropic therapies are utilized to stabilize acute decompensated HF 
patients with low cardiac output. The use of inotropes can be divided into three 
distinct patterns of use: hospital admission for patients presenting with acute 
decompensated HF and end organ involvement, intermittent home infusions 
(several times per week at the infusion center), and continuous home infusion as 
a bridge to cardiac transplantation or for palliation 10-12.  
Inotropes have been used for more than fifty years and continues to be 
the used in patients presenting with low perfusion state due to cardiogenic shock. 
1 The Acute HF Global Survey of Standard Treatment (ALARM-HF) global survey 
of 666 hospitals in nine countries showed that inotropes were used in 39% of all 
admissions for acute HF13.  Furthermore, in the mechanical circulatory support 
(MCS) studies, 72% of patients in the medical arm and 65% of patients in the 
ventricular assist device arm were on inotropes14.  Inotropes successfully improve 
cardiac hemodynamics and patients’ symptoms by increasing myocardial 
contractility mainly by increasing intracellular calcium concentrations. Inotropes 
are crucial in bridging selected patients to cardiac transplantation 15.  
Despite improving hemodynamic compromise, inotropic agents are 
accompanied by increased morbidity and mortality due to increased tachycardia 
and myocardial oxygen consumption leading to arrhythmia, and myocardial 
ischemia 16. This negative effect has been demonstrated in both the hospital and 
outpatient setting.2 Beside digoxin, the current American College of 
Cardiology/American Heart Association, European Society of Cardiology and 
Heart Failure Society of America guidelines endorse that inotropic agents should 
be reserved for patients presenting with acute decompensated HF and low-
output states and reduced end-organ perfusion, who typically are admitted to an 
intensive care unit 2-4. Furthermore, the ACCF/AHA guidelines state specifically 
that use of parenteral inotropic agents in hospitalized patients without 
documented severe systolic dysfunction, low blood pressure, or impaired 
perfusion, and evidence of significantly depressed cardiac output, with or without 
congestion, is potentially harmful. This is based on multiple studies showing 
evidence for harm in patients with advanced HF 16.  
Chronic HF patients who are not eligible for advanced therapies have 
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are based on retrospective studies and post hoc analysis of prospective studies 
16. However, despite the reduced survival, many patients prefer improved quality 
of life, even at the potential expense of a shorter survival. 18,19 The decision to 
use inotropic therapy and the selection of inotropic agent should reflect the 
realistic goals of therapy for the individual with HF. These goals should be 
discussed in great detail with the patient and family.   
Evidence is sufficient to link inotropes to increased mortality 
Based on the current studies that showed increased mortality in patients 
with advanced HF treated with inotropes, the use of inotropes should be limited 
to patients with advanced HF who are not candidates to MCS or heart 
transplantation. In the ADHERE (Acute Decompensated Heart Failure National 
Registry) study17, Abraham et al. performed a retrospective analysis of 
observational patient data from the ADHERE registry where they reviewed over 
65,000 cases admitted for acute decompensated HF from 263 US hospitals 
during October 2001 to July 2003 where they included patients whom had 
received nitroglycerin, nesiritide, milrinone or dobutamine (n= 15,230) therapy 
and assessed risk factor and propensity-adjusted odds ratios for in-hospital 
mortality. What they demonstrated was that use of inotropes doubled the in-
hospital mortality compared to use of vasodilators; 12.3% and 13.9% for patients 
receiving milrinone and dobutamine, respectively, compared to 4.7% and 7.1% 
for patients receiving nitroglycerin and nesiritide, respectively.  Moreover, they 
also found that length of stay was longer compared to those on vasodilator 
therapy, 10.9 and 10 days for patients receiving milrinone and dobutamine, 
respectively, compared to 7.1 and 7.9 days for patients receiving nitroglycerin 
and nesiritide, respectively.   
Inotropic dependence is defined as the failure to wean from inotropes 
because of imminent (minutes to hours) worsening of the patient’s clinical status 
such that death appeared impending, and the patient is deemed highly unlikely to 
survive inotrope withdrawal to permit hospital discharge 20.  In other words, 
withdrawal of inotropic support in this cohort of patients can be acutely life-
threatening 2,20.  
 Furthermore, in the OPTIME-CHF (Outcomes of a Prospective Trial of 
Intravenous Milrinone for Exacerbations of Chronic HF) trial 21, Cuff et al. 
demonstrated in this prospective study that intravenous (IV) milrinone used in 
chronic HF patients, admitted for acute decompensated HF, increased morbidity 
associated with hypotension and new atrial arrhythmias but no significant 
difference in in-hospital mortality or 60-day mortality. As an extension of the 
OPTIME-CHF trial, Felker et al. 22analyzed the interaction of the etiology of HF 
(ischemic vs. non-ischemic) with IV milrinone and found that patients with 
ischemic HF were not only hospitalized longer (13 days vs. 11.7 days) but also 
had increased 60-day mortality (11.6% vs. 7.5%) compared to patients with non-
ischemic cardiomyopathy. In this study, 22% of patients were started on beta-
blockers on admission. Thus, the “neutralizing” effect of beta-blockers for 
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neutralizing effect of milrinone and showed decrease incidence of death or re-
hospitalization in non-ischemic group suggesting neutralizing effect.  However, 
the study had limitation since it was retrospective post-hoc analysis and authors 
did not clarify the definition of ischemic cardiomyopathy. Furthermore, double the 
patients in the non-ischemic cardiomyopathy group were lost to follow up 23.   
In spite of increased mortality seen in the inpatient setting as seen in the 
ADHERE study, the consideration of intermittent inotropic therapy has also been 
studied in the outpatient setting. With a varying array of treatment regimens as 
well as administration from daily to weekly regimens, some with concomitant use 
of amiodarone as an antiarrhythmic, there has been some evidence of improved 
symptoms, decreased hospitalization and short term mortality, but the studies 
were small and observational in nature and failed to demonstrate “true” benefit of 
intermittent inotropic therapy 18,24,25.  
Inotropes Use in Palliative and Hospice Care 
Due to lack of evidence for mortality benefit association with inotropes in 
ADHF patients, inotropes were studies in hospice care and palliative care 
settings. 20 In one prospective study, the author suggested that intermittent 
infusion of intravenous inotropes is can modify end-stage HF symptoms, improve 
functional class and may also facilitate better utilization of hospice and palliative 
care resources among patients with end-stage heart. 26 The current HF 
guidelines suggest that long-term, continuous intravenous inotropic support may 
be considered as palliative therapy for symptom control in select patients with 
stage D HF despite optimal medical therapy and device therapy who are not 
eligible for either MCS or cardiac transplantation. 2  
Mechanical Circulatory Assist Devices – A Game Changer in End-
Stage HF management 
Prior to the advent of left ventricular assist devices (LVAD), patients with 
end-stage HF who were ineligible for heart transplant did not have many options 
except for palliative care or palliative inotropic therapy which was not a viable 
long term treatment strategy.  To evaluate the efficacy of LVADs, the REMATCH 
(Randomized Evaluation of Mechanical Assistance for the Treatment of 
Congestive HF) trial from May 1998 to July 2001 randomized 128 patients to 
either LVAD or optimal medical therapy 14. Their findings were remarkable. 
Survival at one year was 52% in the device group and 25% in the medical group.  
The observed mortality of 75% at 1 year in the medical group approaches 
mortality rates seen in pancreatic cancer. Of note, however, patients in the 
device group were twice as likely to have a serious adverse effect, namely, 
infection, bleeding or malfunction of device, but overall had improved quality of 
life compared to medical group. Moreover, the INTrEPID (Investigation of Non-
transplant Eligible Patients who are Inotropic Dependent) 27 trial which was a 
prospective nonrandomized clinical trial comparing LVAD to optimal medical 
therapy enrolled 55 patients between March 2000 and May 2003 who were 
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device group and 22% in the medical group and survival at 1 year was 27% in 
the device group and 11% in the medical group. Further, 85% of the LVAD 
patients demonstrated either no symptoms or minimal HF symptoms compared 
to the medical group, whom experienced no improvement in functional NYHA 
class. Results of the REMATCH and INTrEPID trial demonstrated that patients 
with end-stage HF have dismal survival rates on optimal medical therapy, but do 
far much better with mechanical support as well as have improved quality of life.  
With evidence of the benefits of mechanical support compared to 
inotropic therapy for end-stage HF, it is essential to consider mechanical support 
as the first line treatment in patients with end-stage HF, with inotropes being 
reserved to acutely stabilize the patient as a bridge to MCS or for palliation.  
Further, future research should not be directed to development of novel inotropic 
agents as by definition any drug that increases myocardial contractility will result 
in increase myocardial oxygen demand, which is associate with worse outcomes. 
Medical therapy in end stage HF is obsolete and this is the era of mechanical 
circulatory support. Although inotropes may be useful as a short-term strategy to 
help temporize acute hemodynamic instability in cardiogenic shock, the clear 
increase in mortality and morbidity with its use should be weighed against the 
benefit of a more durable, long-term treatment strategy with mechanical assist 
devices. 
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